Akesa
Akesa is an Australian clinical trial supply company that sources comparator drugs, standard-of-care medications, and co-therapies for pharmaceutical sponsors, CROs, and CDMOs across APAC. It operates digital platforms Aksys and Clincor alongside managed access programs and validated global logistics for 1,500+ trials supported since 2014.
- Company typePrivate
- Founded2014
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Akesa does
Akesa is an Australian-headquartered clinical trial supply company founded in 2014 that specializes in sourcing comparator drugs, standard-of-care medications, and co-therapy products for pharmaceutical and biotechnology sponsors, contract research organisations (CROs), and contract development and manufacturing organisations (CDMOs). The company operates across four licensed jurisdictions (Australia, New Zealand, Singapore, and Japan) and distributes to clinical trial sites and patients across the Asia-Pacific region, USA, Europe, and the UK, having supplied 1,500+ clinical trials cumulatively with approximately 50% being Phase 3 global trials. Its core technology consists of two cloud-based SaaS platforms: Aksys, a digital ordering and fulfillment platform for hospital pharmacies to source non-PBS reimbursed medicines (currently anchored by an exclusive partnership with Novartis Australia and deployed across 90+ public hospitals), and Clincor, an on-demand clinical trial pharmacy site solution enabling real-time access to comparator and co-therapy medicines for sponsors, pharmacies, and trial sites.
The company's business model is a hybrid of managed services and SaaS. Revenue is generated through clinical trial supply services (sourcing, procurement, warehousing, and cold-chain logistics on a per-project basis), managed access programs (compassionate, early, and post-trial access programs), and digital platform subscriptions (Aksys). Pricing is quote-based and negotiated per trial or per program, with multi-year contracts typical for enterprise engagements. Akesa maintains validated GxP and ISO 9001 quality systems, a validated global supplier network, and direct manufacturer relationships across multiple regulatory frameworks (TGA, PMDA, HSA, and EU GDP). The company is privately held, founder-led by co-CEOs Con Konstantopoulos and George Vlachos, and has not disclosed external funding rounds. Go-to-market combines direct enterprise sales to pharmaceutical sponsors and CROs, exclusive digital platform partnerships, event-driven thought leadership, and operational deployments in partnership with hospital pharmacies across APAC.
Akesa firmographics
Firmographics- Name
- Akesa
- Legal name
- Akesa Pty Ltd
- Website
- https://akesagroup.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Akesa is an Australian clinical trial supply company that sources comparator drugs, standard-of-care medications, and co-therapies for pharmaceutical sponsors, CROs, and CDMOs across APAC. It operates digital platforms Aksys and Clincor alongside managed access programs and validated global logistics for 1,500+ trials supported since 2014.
- Ownership category
- akta.pro rank
Akesa industry classification
Industry- Product category
- Clinical Trial Supply Services
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Direct-to-Provider / Clinic Buy-and-Bill Distributors (HLAIAJAM)
- akta.pro secondary industries
- Patient Access Programs & Affordability (Copay/Hubs/PSP) (HLAIAKAG), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)
Keywords
Where Akesa is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices5 records
Markets served
Akesa business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Supply Services: Akesa provides clinical trial supply services including sourcing, procurement, and logistics for comparator drugs, concomitant medications, and standard-of-care products. The company manages complex supply projects and delivers trial supplies across the Asia-Pacific region and globally to clinical trial sites and directly to patients.
- Digital Platform Services (Aksys): SaaS platform providing a compliant supply channel for non-PBS reimbursed medicines to hospital pharmacies. The platform streamlines product procurement, order tracking, payment processing, and product management for private-script medicines.
- Managed Access Programs: Structured governance programs enabling patients to access medicines before routine availability. Services include bridging the gap between clinical trial conclusion and widespread treatment availability, supporting compassionate access, early access, post-clinical trial access, and patient support programs.
- Warehouse and Logistics Services: Warehousing logistics, temperature-controlled storage, and distribution services ensuring validated secure supply and robust supply chain management for clinical trial products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing for clinical trial supply services |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Akesa product offering
Product offeringCore offering
Akesa sources comparator drugs, concomitant therapies, and standard-of-care medications for Phase I–IV clinical trials, and provides managed access programs that bridge clinical trials to commercial availability. The company operates two proprietary digital platforms—Aksys for hospital pharmacies to order non-PBS reimbursed medicines, and Clincor for on-demand clinical trial pharmacy supply—and supports these with warehousing, cold-chain logistics, and direct-to-site or direct-to-patient distribution.
Product overview
Akesa offers a portfolio of clinical trial supply and pharmaceutical access solutions comprising two primary digital platforms (Aksys and Clincor) and associated service offerings. Aksys is a hospital-focused digital ordering platform for private-script medicines, while Clincor is an on-demand clinical trial pharmacy solution enabling real-time sourcing of comparators and co-therapies. These platforms are supported by managed access programs, supplier access services, and warehousing/logistics capabilities. The company serves pharmaceutical companies, CDMOs, CROs, clinical trial sites, and hospitals across the APAC region and globally.
Differentiator
Problem solved
Functional benefit
Products and services
- Aksys Cloud-based SaaS digital ordering and fulfilment platform for hospital pharmacies and healthcare providers to source non-PBS reimbursed private-script medicines directly from manufacturers. It provides a single compliant supply channel managing procurement, order tracking, payment processing, customer support and delivery.
- Clincor On-demand clinical trial pharmacy site solution that simplifies the supply chain and facilitates seamless administration between sponsor, pharmacy and clinical trial site. CT Connect enables clinical trial sponsors to access comparator and co-therapy medicines in real time.
- Akesa Clinical Trial Supply Strategic clinical trial supply services for pharmaceutical and biotechnology sponsors, including sourcing of comparator drugs, standard-of-care medications, concomitant therapies and biosimilar trial supplies, plus tailored sourcing strategies, supplier access, warehousing logistics and global distribution to support trials across APAC and beyond.
- Managed Access Programs Structured programs enabling patients to access medicines before routine availability, including compassionate access, early access, post-clinical trial access, and patient support programs that bridge the gap between clinical trial conclusion and widespread treatment availability.
- Supplier Access Service providing access to Akesa's global network of validated suppliers and manufacturers for clinical trial pharmaceutical products, enabling reliable delivery of trial supplies with validated supply chain infrastructure.
- Warehousing and Logistics Temperature-controlled storage and distribution services for clinical trial supplies, including cold chain logistics and validated storage infrastructure compliant with GDP and GWP standards, supporting direct-to-site and direct-to-patient distribution.
Quantifiable outcome
- Enabled supply of life-saving therapies in 90+ public hospitals through Aksys platform
- +2 more outcomes
Companies that use Akesa
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles4 records
Akesa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Akesa partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Novartis Pharmaceuticals AustraliacoreExclusive partnership for the Aksys digital platform. Novartis enrolled first in the Hospital Ordering Program (HOP) enabling hospitals to access Novartis catalogue of medicines for on-label and non-PBS dispensing through one digital platform. The partnership simplifies ordering for healthcare institutions and provides direct access to medicines while improving commercial viability and program scalability for manufacturers.
- Rock8 SciencecoreStrategic partnership to strengthen pharmaceutical supply chains in the Asia-Pacific region. The collaboration addresses increasing demand for commercial medicines in clinical trial settings, ensuring studies across APAC have reliable access to essential pharmaceutical products. Rock8 Science provides real-time insights to help manufacturers anticipate trial-related demand fluctuations, reducing supply disruption risks and commercial stock shortages.
- The Pharmacy Common (TPC)coreCollaboration for managed access program delivery supporting dialysis patient medication management. TPC handled order management, medication dispensing and packaging, shipping and tracking, and prescription renewal communication. The partnership demonstrated seamless delivery of medications directly to patients' homes across Australian states.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Akesa competitors and assessment
Company assessmentDirect peers
- Marken (UPS Healthcare): Global clinical trial logistics and supply chain specialist, now part of UPS Healthcare. Directly comparable to Akesa on direct-to-site and direct-to-patient distribution, cold chain, and comparator sourcing.
- Almac Group: Global pharma services provider offering clinical trial supply, comparator sourcing, packaging, and distribution. Closely aligned with Akesa on end-to-end clinical trial supply chain services.
- PCI Pharma Services: Global clinical trial services provider including clinical trial supply, comparator sourcing, packaging, and global distribution. Strong overlap with Akesa's core clinical trial supply and packaging-adjacent services.
- DHL Supply Chain (Life Sciences): Global logistics provider with dedicated Life Sciences / Clinical Trials division offering comparator sourcing, cold chain, and direct-to-patient distribution. Direct competitor to Akesa's logistics-heavy service lines.
- Clinigen Group: UK-headquartered pharma services company with managed access programs, clinical trial supply, and unlicensed medicines distribution. Direct competitor to Akesa's managed access and comparator sourcing offerings.
- Myoderm: US-based clinical trial supply specialist focused on comparator and co-therapy drug sourcing, packaging, and distribution. Directly comparable niche focus to Akesa's clinical trial supply business.
Broad incumbents
- Thermo Fisher Scientific (Clinical Trials Services): Diversified life sciences giant with PPD clinical research services including clinical trial supply, comparator sourcing, and central labs. Larger incumbent offering overlapping capabilities within a much broader portfolio.
- Catalent (Novo Holdings): Major global pharma services provider with clinical trial supply, comparator sourcing, and patient access services across multiple regions. Broad incumbent with overlapping CTS offerings.
- IQVIA: Largest global CRO with comprehensive clinical trial supply capabilities alongside broader clinical research and commercial services. Akesa competes with IQVIA's CTS offering, and George Vlachos (Akesa co-CEO) is a former IQVIA senior leader.
- Parexel International: Major global CRO providing clinical trial supply solutions alongside broader clinical research services. Competes with Akesa for CTS contracts from large pharma sponsors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Akesa social profiles
Digital presenceAkesa compliance and trust
Trust signalCompliance3 records
Akesa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Akesa leadership team
Management profileNumber of profiles
Profiles8 records
Akesa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Akesa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Akesa
What does Akesa do?
Akesa sources comparator drugs, concomitant therapies, and standard-of-care medications for Phase I–IV clinical trials, and provides managed access programs that bridge clinical trials to commercial availability. The company operates two proprietary digital platforms—Aksys for hospital pharmacies to order non-PBS reimbursed medicines, and Clincor for on-demand clinical trial pharmacy supply—and supports these with warehousing, cold-chain logistics, and direct-to-site or direct-to-patient distribution.
Is Akesa a public or private company?
Akesa is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Akesa founded?
Akesa was founded in 2014. It employs 11 to 50 people.
Where is Akesa based?
Akesa is headquartered in Melbourne, Australia, in the Oceania region.
How does Akesa make money?
Four revenue lines are on record. Clinical Trial Supply Services are the primary driver. The others are digital Platform Services (Aksys), managed Access Programs and warehouse and Logistics Services.
Who are Akesa's main competitors?
Direct peers on record are Marken (UPS Healthcare), Almac Group, PCI Pharma Services, DHL Supply Chain (Life Sciences), Clinigen Group and Myoderm. Broad incumbents are Thermo Fisher Scientific (Clinical Trials Services), Catalent (Novo Holdings), IQVIA and Parexel International.
Does Akesa have an API?
No public API is recorded for Akesa.
What industry is Akesa in?
Akesa's product category is Clinical Trial Supply Services. Its primary akta.pro industry code is HLAIAJAM, Direct-to-Provider / Clinic Buy-and-Bill Distributors, with a secondary code of HLAIAKAG, Patient Access Programs & Affordability (Copay/Hubs/PSP). Its NAICS code is 42421 and its SIC code is 5122.